Stable bioavailability of cyclosporin A, regardless of food intake, from soft gelatin capsules containing a new self-nanoemulsifying formulation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 5, 2006, Pages 233-239

  Yang, S G ^a   Kim, D D ^a   Chung, S J ^a   Shim, C K ^a  

^a Seoul National University   (South Korea)

Author keywords

Bioavailability; Bioequivalence; Cyclosporin A; Food effects; Micro emulsion

Indexed keywords

CYCLOSPORIN A; GELATIN; TRIACETIN;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FEVER; DRUG FORMULATION; EMULSION; FOOD DRUG INTERACTION; FOOD INTAKE; HEAT SENSATION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MEAL; NORMAL HUMAN; OPEN STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; VOLUNTEER;

EID: 33646399168     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44233     Document Type: Article

References (22)

1. Allen ME, Vandenburg MJ. Good Clinical Practice: rules, regulations and their impact on the investigator. Br J Clin Pharmacol. 1992; 33: 463-465.
2. Andrysek T. Impact of physical properties of formulations on bioavailability of active substance: current and novel drugs with cyclosporine. Mol Immunol. 2003; 39: 1061-1065.
3. Brunner LJ, Pai KS, Munar MY, Lande MB, Olyaei AJ, Mowry JA. Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant. 2000; 4: 313-321.
4. Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res. 2003; 20: 749-756.
5. Duplay D. Physicians' desk reference. Montvale, NJ: Thomson Healthcare; 2005.
6. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, Benet LZ. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol. 1990; 30: 643-653.
7. Henney JE. From the Food and Drug Administration. JAMA. 2000; 284: 1234.
8. Honcharik N. The effect of food on cyclosporine absorption. Clin Biochem. 1991; 24: 89-92.
9. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004; 143: 856-864.
10. Howard-Jones N. Human experimentation in historical and ethical perspectives. Soc Sci Med. 1982; 16: 1429-1448.
11. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc. 2004; 36: 378S-391S.
12. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation. 1995; 59: 505-511.
13. Kees F, Mair G, Dittmar M, Bucher M. Cicloral versus Neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of Cicloral. Transplant Proc. 2004; 36: 3234-3238.
14. Kovarik JM, Barilla D, McMahon L, Wang Y, Kisicki J, Schmouder R. Administration diluents differentiate Neoral from a generic cyclosporine oral solution. Clin Transplant. 2002; 16: 306-309.
15. Martinez M, Augsburger L, Johnston T, Jones WW. Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations. Adv Drug Deliv Rev. 2002; 54: 805-824.
16. Mueller EA, Kovarik JW, van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res. 1994a; 11: 151-155.
17. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 1994b; 11: 301-304.
18. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and "self-microemulsifying" drug delivery systems. Eur J Pharm Sci. 2000; 11 (Suppl 2): 93-98.
19. Schroeder TJ, Hariharan S, First MR. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant Proc. 1995; 27: 837-839.
20. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
21. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005; 22: 11-23.
22. Yang SG. A novel nano delivery system of cyclosporin A with enhanced physical stability. Seoul: Seoul National University; 2006.